Elanco Raises Full-Year Outlook After Q3 Revenue Climbs 11% to $1.27 Billion
Elanco Animal Health Incorporated reported third-quarter 2026 revenue of $1.265 billion, up 11% year over year, or 9% on an organic constant-currency basis, according to an 8-K furnished Friday.
Reported net income was $18 million, or $0.04 per share. Adjusted net income was $136 million, or $0.27 per share. Adjusted EBITDA was $243 million, for a margin of 19.5%. Net leverage stood at 2.9x Adjusted EBITDA.
Guidance raised
Elanco raised full-year 2026 revenue guidance to $5.155 billion to $5.18 billion, Adjusted EBITDA to $1.05 billion to $1.065 billion, and Adjusted EPS to $1.17 to $1.20. It also lifted its innovation revenue target to $1.275 billion and improved its year-end net leverage target to an estimated 2.9x Adjusted EBITDA. Organic constant-currency revenue growth is now expected at 8%, up from a prior 6% to 7%.
CEO Jeff Simmons said price rose 4% in the quarter and volume 5%, with International Pet Health up 17% and U.S. Pet Health up 13% on an organic constant-currency basis. Zenrelia and Credelio Quattro reached new market-share highs in September, the company said.
By the numbers
- Q3 revenue: $1.265 billion, up 11%
- Adjusted EPS: $0.27
- Adjusted EBITDA: $243 million
- 2026 revenue guidance: $5.155 billion to $5.18 billion
- 2026 Adjusted EPS guidance: $1.17 to $1.20
Sources
- Elanco Form 8-K with third-quarter 2026 earnings release (Exhibit 99.1), filed Nov. 6, 2026 (accession 0001739104-26-000054)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.